Immunogenicity of a meningococcal serogroup C conjugate vaccine in HIV-infected children, adolescents, and young adults

Bertolini, Daniela Vinhas; Costa, Luciana Scarlazzari; Heijden, Inneke M. van der; Sato, Helena Keiko; Marques, Heloísa Helena de Sousa

doi:10.1016/j.vaccine.2012.06.069

Cited by 21 publications

(16 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study was consistent with other studies that demonstrated that MCC vaccine was safe and immunogenic in HIV-uninfected individuals (29,32,33), although the seroconversion rate was lower than previously described in healthy children (84–99%)(29,32) and adolescents (85–100%) (25,34). The reasons for this lower response rate among HIV-uninfected population in our study are unknown.…”

Section: Discussionsupporting

confidence: 93%

“…There are few data about the use of MCC vaccine in HIV-infected children and adolescents (25). The primary aim of this study was to evaluate short-term immunogenicity following administration of a single dose of MCC vaccine in HIV-infected children and adolescents at a reference center in Rio de Janeiro, Brazil, and to compare their response to HIV-uninfected subjects.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunogenicity and Safety of Meningococcal C Conjugate Vaccine in Children and Adolescents Infected and Uninfected with HIV in Rio de Janeiro, Brazil

Frota¹,

Milagres

Harrison

et al. 2015

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

Background We aimed to evaluate the Neisseria meningitidis C conjugated vaccine (MCC) seroconversion and adverse events (AE) in HIV-infected and uninfected children and adolescents in Rio de Janeiro, Brazil. Methods HIV-infected or uninfected subjects, 2–18 years old, with CD4+ T-lymphocyte cell (CD4) percentage >15%, without active infection or antibiotic use, were enrolled. All patients were evaluated before and 1–2 months after immunization for seroconversion (defined as ≥4-fold titer increase in human serum bactericidal activity), and for AEs at 20 minutes, 3 and 7 days after immunization. Factors associated with seroconversion among HIV-infected group were studied. Results 204 subjects were enrolled: 154 HIV-infected and 50 HIV-uninfected. Median age was 12 years and 53% were female. Among the HIV-infected group, 82 (53%) had a history of at least one C clinical category Centers for Diseases Control and Prevention event, and 134 (87%) were using combination antiretroviral therapy (cART). The median nadir CD4 percentage was 13% (0%–47%). 76(37.3%) experienced mild AEs. Seroconversion occurred in 46/154 (30%) of the HIV-infected group, and in 38/50 (76%) of the uninfected group (p<0.01). Factors associated with seroconversion in the HIV-infected group were: Never had a C clinical category event (OR=2.1, 95%CI=1.0–4.4); undetectable viral load at immunization (OR=2.4, 95%CI=1.1–5.2), and higher CD4 nadir/100 cells (OR=1.1, 95%CI=1.0–1.2). Conclusion MCC vaccine should be administered to HIV-infected children and adolescents after maximum immunologic and virologic benefit has been achieved with cART. Our data suggest that a single dose of MCC vaccine is insufficient for HIV-infected individuals 2–18 years of age.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Immunogenicity and Safety of Meningococcal C Conjugate Vaccine in Children and Adolescents Infected and Uninfected with HIV in Rio de Janeiro, Brazil

Frota¹,

Milagres

Harrison

et al. 2015

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

show abstract

“…82 In another study among young HIV patients, lower immune responses were also noted (seroconversion to A: 68%; C: 52%; Y: 73%; and W-135: 63%), with poorer response rates among those with more advanced HIV disease. 83 Regarding the number of doses, a study found that two doses (versus one) significantly improved response rates among those with CD4% ‡ 15%, but that those with a low CD4% ( < 15%) had poor responses in both groups.…”

Section: Meningococcalmentioning

confidence: 95%

Vaccination in HIV-Infected Adults

Crum-Cianflone

Wallace

2014

AIDS Patient Care and STDs

View full text Add to dashboard Cite

Vaccines are critical components for protecting HIV-infected adults from an increasing number of preventable diseases. However, missed opportunities for vaccination among HIV-infected persons persist, likely due to concerns regarding the safety and efficacy of vaccines, as well as the changing nature of vaccine guidelines. In addition, the optimal timing of vaccination among HIV-infected adults in regards to HIV stage and receipt of antiretroviral therapy remain important questions. This article provides a review of the current recommendations regarding vaccines among HIV-infected adults and a comprehensive summary of the evidence-based literature of the benefits and risks of vaccines among this vulnerable population. Importance of Vaccinations for HIV Patients

show abstract

“…The only comparative study to date, conducted in Brazil in HIV-infected children, adolescents and young adults, showed a lower immunogenicity compared to seronegative controls (72.1% of the HIV-infected patients were responders to a single dose of meningococcal C conjugate vaccine -this rate increased to 81.4% when those receiving a second dose were included, while 100% of the non-HIV-infected persons achieved protective levels after receiving the first dose). 75 Factors associated with seroconversion were: never had AIDS clinical event, undetectable HIV viral load at immunization and higher CD4 nadir. 76 In a phase I/II trial evaluating the safety and immunogenicity of a quadrivalent A,C,W135,Y conjugate vaccine (MCV4) in HIV-infected children and young adults (11-24 years old), the responder rates to serogroups A, C, W-135, and Y were 68%, 52%, 73%, and 63%, respectively.…”

Section: Meningococcal Vaccinementioning

confidence: 99%

Immunization of HIV-infected adult patients — French recommendations

Frésard

Gagneux‐Brunon

Lucht

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Human immunodeficiency virus (HIV)-infected patients remain at increased risk of infection including vaccine-preventable diseases. Vaccines are therefore critical components in the protection of HIV-infected patients from an increasing number of preventable diseases. However, missed opportunities for vaccination among HIV-infected patients persist and vaccine coverage in this population could be improved. This article presents the French recommendations regarding immunization of HIV-infected adults in the light of the evidence-based literature on the benefits and the potential risks of vaccines among this vulnerable population.

show abstract

Immunogenicity of a meningococcal serogroup C conjugate vaccine in HIV-infected children, adolescents, and young adults

Cited by 21 publications

References 27 publications

Immunogenicity and Safety of Meningococcal C Conjugate Vaccine in Children and Adolescents Infected and Uninfected with HIV in Rio de Janeiro, Brazil

Immunogenicity and Safety of Meningococcal C Conjugate Vaccine in Children and Adolescents Infected and Uninfected with HIV in Rio de Janeiro, Brazil

Vaccination in HIV-Infected Adults

Immunization of HIV-infected adult patients — French recommendations

Contact Info

Product

Resources

About